Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis

被引:123
作者
Hutchinson, Carol
Geissler, Catherine A.
Powell, Jonathan J.
Bomford, Adrian
机构
[1] Kings Coll Hosp London, Inst Liver Studies, Iron Metab Interdisciplinary Res Grp, London SE5 9RS, England
[2] MRC Human Nutr Res, Cambridge, England
基金
英国医学研究理事会;
关键词
D O I
10.1136/gut.2006.108613
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: During the long-term treatment of patients with hereditary haemochromatosis (HH) the authors observed that proton pump inhibitors (PPI) reduced the requirement for maintenance phlebotomy. Gastric acid plays a crucial role in non-haem iron absorption and the authors performed a case review and intervention study to investigate if PPI-induced suppression of gastric acid would reduce dietary iron absorption in C282Y homozygous patients. Methods: Phlebotomy requirements to keep serum ferritin similar to 50 mu g/l before (mean 6.1 (SE 0.6) years) and during (3.8 (0.9) years) administration of a PPI were evaluated in seven patients and a post-prandial study was performed to determine whether PPIs reduce absorption of non-haem iron (14.5 mg) from a test meal in a further 14 phlebotomised patients with normal iron stores. Results: There was a significant reduction (p < 0.001) in the volume of blood removed annually before (2.5 (0.25) l) and while taking (0.5 (0.25) l) a PPI. Administration of a PPI for 7d suppressed absorption of non-haem iron from the meal as shown by a significant reduction (all p < 0.01) in: area under the serum curve (2145 (374) versus 1059 (219)), % recovery of administered iron at peak serum iron (20.5 (3.2) versus 11.0 (2.0)%) and peak serum iron (13.6 (2.4) vs 6.1 (1.2) mu mol/l) (all values are before vs during PPI). Conclusions: Administration of a PPI to patients with HH can inhibit the absorption of non-haem iron from a test meal and the habitual diet.
引用
收藏
页码:1291 / 1295
页数:5
相关论文
共 40 条
[1]  
ARCHAMBAULT AP, 1967, GASTROENTEROLOGY, V52, P940
[2]  
BEZWODA W, 1978, J LAB CLIN MED, V92, P108
[3]   Genetics of haemochromatosis [J].
Bomford, A .
LANCET, 2002, 360 (9346) :1673-1681
[4]  
BOMFORD A, 1976, Q J MED, V45, P611
[5]   Disrupted hepcidin regulation in HFE-associated haemochromatosis and the liver as a regulator of body iron homoeostasis [J].
Bridle, KR ;
Frazer, DM ;
Wilkins, SJ ;
Dixon, JL ;
Purdie, DM ;
Crawford, DHG ;
Subramaniam, VN ;
Powell, LW ;
Anderson, GJ ;
Ramm, GA .
LANCET, 2003, 361 (9358) :669-673
[6]  
Champagne E T, 1989, Adv Exp Med Biol, V249, P173
[7]   Serum iron curves can be used to estimate dietary iron bioavailability in humans [J].
Conway, Rana E. ;
Geissler, Catherine A. ;
Hider, Robert C. ;
Thompson, Richard P. H. ;
Powell, Jonathan J. .
JOURNAL OF NUTRITION, 2006, 136 (07) :1910-1914
[8]  
DAVIS WD, 1952, J LAB CLIN MED, V39, P526
[9]  
Dooley J., 2000, GUIDELINES DIAGNOSIS, P1
[10]   Expression of hepcidin in hereditary hemochromatosis: evidence for a regulation in response to the serum transferrin saturation and to non-transferrin-bound iron [J].
Gehrke, SG ;
Kulaksiz, H ;
Herrmann, T ;
Riedel, HD ;
Bents, K ;
Veltkamp, C ;
Stremmel, W .
BLOOD, 2003, 102 (01) :371-376